Lung Cancer Vaccine MAGE-A3 Does Not Improve Disease-Free Survival in Resected Lung Cancer

At ESMO 2014, Prof Johan F. Vansteenkiste summarises the results of the MAGRIT trial, a phase III trial which showed that MAGE-A3 cancer immunotherapy did not increase disease-free survival in patients with resected NSCLC.

Year of Production:
Running Time:
Color/Sound:

2014

Color/Sound

Comments are closed.